Altana/Nycomed — Papillion, Nebraska

Altana/Nycomed is a clinical research site located in Papillion, Nebraska, United States 68046.

Crixeo Clinical Trials Trust Score: 11/100 (FAILING). This profile has not yet been claimed by the site owner.

Altana/Nycomed has participated in 2 clinical trials.

Therapeutic areas: Rhinitis, Allergic, Seasonal, Rhinitis, Allergic, Perennial.

Sponsors: AstraZeneca.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Papillion

Browse all research sites in Nebraska · View every site in Papillion

• Midlands Cancer Center at Midlands Community Hospital
• Midlands Community Hospital
• Alegent Health-Midlands Community Hospital
• Alegent Health Midlands Hospital
• GSK Investigational Site
• Research Site
• Novartis Investigative Site
• The Asthma and Allergy Center
• Cognitive Clinical Trials (CCT) - Papillion /ID# 248536
• Asthma & Allergy Center, P.C.
• Investigational Site Number 840004
• The Asthma & Allergy Center, PC

Sponsor Feasibility Report

Trust Score: 11/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Altana/Nycomed?

Altana/Nycomed has a Crixeo Trust Score of 11/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Altana/Nycomed conducted?

Altana/Nycomed has 2 clinical trials on record. Their work covers Rhinitis, Allergic, Seasonal, Rhinitis, Allergic, Perennial.

Is Altana/Nycomed accredited by Crixeo Clinical Trials?

Altana/Nycomed has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Altana/Nycomed?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.